Business · 04/09/2018Updated: 10/17/2026 · 1 min read
FDA Renews Endocrinologic and Metabolic Drugs Advisory Committee for 2 Years
The FDA has renewed the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on August 27, 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →